Article Text

PDF
ASSA14-02-10 Clinical research of ch-BNP in treatment of patients with acute left heart failure
  1. Y Guitang,
  2. L Ya,
  3. Zulu Wang,
  4. L Yanchun,
  5. S Yi,
  6. L Rong,
  7. X Guoqing,
  8. H Yaling
  1. Department of Cardiology, Institute of Cardiovascular Research of People’s Liberation Army, Shenyang General Hospital, Shenyang, Liaoning 110840, China

Abstract

Objective To retrospectively investigate the effectiveness and safety of ch-BNP in treatment of patients with acute left heart failure.

Methods Ninety-nine patients with acute left heart failure were studied and randomly divided into two groups: control group (n = 48) with normal treatment and ch-BNP group (n = 51) with normal treatment + ch-BNP. ch-BNP 1.5–2 mg/kg bolus, 0.0075–0.01 mg/kg/min was given intravenously everyday for 5–7 days. The heart functions of the patients were evaluated and the heart indexes, adverse effect were monitored after the seven administrations.

Results The rates of heart function improvement in the ch-BNP group were higher than that in the control group (83.4% vs 54.2%, p < 0.05). There was not significantly adverse drug reaction.

Conclusion ch-BNP in treatment of patients with acute left heart failure is effective and safe.

Statistics from Altmetric.com

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.